U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07708025) titled 'Oral Iron for the Management of Iron Deficiency Anemia in SGLT2i-Treated Heart Failure Patients' on April 13.
Brief Summary: People with heart failure often have anemia caused by low iron levels. Ongoing inflammation in heart failure can impair iron absorption, making oral iron therapy less effective.
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are medications used to treat heart failure. In addition to their cardiovascular benefits, these drugs may improve iron metabolism and support red blood cell production.
This study evaluates whether patients with heart failure and iron deficiency anemia who are receiving SGLT2i ther...